Dr. Wohl is a clinical scientist with a focus on emergent infectious diseases. He has spent over 20 years leading research into the prevention and treatment of HIV and served two terms as a member of the US Department of Health and Human Services (DHHS) Antiretroviral Guidelines Panel. Since 2014, he has been working continuously in Liberia, West Africa, conducting research with Ebola survivors to learn about chronic complications and sexual transmission of this infection and establishing the UNC Project Liberia research platform at two locations in the country. He and his team have extended this work to examine Lassa fever, a viral hemorrhagic fever endemic in West Africa. In 2020, he helped lead the UNC clinical and research response to COVID-19. He is medical director of a large drive through testing site as well as two COVID-19 vaccination clinics. He serves as Vice Chair of ACTIV-2, an international AIDS Clinical Trials Group (ACTG)/Operation Warp Speed trial of SARS-CoV-2 therapeutics. He has an active clinical practice at UNC.